Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Frequently asked questions
What sector does Savara Inc (SVRA) operate in?
Savara Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Savara Inc (SVRA) current stock price?
As of the latest data, Savara Inc stock price is $4.52, with a previous close of $4.22. Savara Inc gained $0.30 in the last trading session, representing a 7.11% increase.
What is Savara Inc (SVRA) current market capitalization?
Savara Inc market cap is approximately 926.27 million.
What is Savara Inc (SVRA) Earnings Per Share (EPS)?
The trailing EPS is -$0.58, and the forward EPS is -$0.31.
What is Savara Inc (SVRA) EBITDA?
Savara Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -40.20 million.
Does Savara Inc (SVRA) pay dividends?
No. Savara Inc does not pay a dividend.
What is Savara Inc (SVRA) beta (volatility) score?
Savara Inc has a beta of 0.252, indicating lower volatility than the overall market.